[Prognostic genomic tests in early breast cancer: MammaPrint® and Oncotype DX®]
Martínez-Férez IM, Márquez-Peláez S, Isabel-Gómez R, Beltrán-Calvo C.
Record ID 32014001022
Spanish
Original Title:
Pruebas genómicas para el pronóstico de pacientes con cáncer de mama. MammaPrint® y Oncotype DX®.
Authors' objectives:
The aim of this study was to assess the efficacy and clinical utility of Onco-type DX® and MammaPrint®, as prognostic and/or predictive tests of breast cancer, and their efficiency and impact on adjuvant therapy recommendations.
Authors' recommendations:
The MammaPrint® is an independent prognosis factor in EBC, but there is insufficient evidence of its predictive ability in patients with ER-positive cancer treated with tamoxifen.
The discordance rate between MammaPrint® and clinicopathological parameters was 27%-48%. The use of MammaPrint® reduced the proportion of high risk patients as classified by AOL by 8%-20%.
In ER positive patients, HER2 negative MammaPrint® would change the decision of adjuvant therapy in 18-29% of cases.
Oncotype DX® is a prognostic and predictive factor in ER-positive breast cancer treated with tamoxifen and the use of Oncotype® has been increased during the last years.
The Oncotype DX® modified the decision of adjuvant therapy in 30-32% of cases. The predominant change was from a combined adjuvant chemohormonal therapy to a hormonal therapy alone; so Oncotype DX® meant a reduction of adjuvant chemotherapy. The test impact on decision-making could be greater in patients with node-positive than in patients with node-negative.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
https://www.aetsa.org/publicacion/pruebas-genomicas-para-el-pronostico-de-pacientes-con-cancer-de-mama-mammaprint-y-oncotype-dx/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Breast Neoplasms
- Early Detection of Cancer
Keywords
- Breast Neoplasms
- Genomics
- Gene Expression Profiling
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.